Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Mesothelioma, Malignant 1

Interventions

pembrolizumab 41Injections 39toripalimab 23Nivolumab 22Cisplatin 19Pemetrexed 18Carboplatin 18Cyclophosphamide 17Paclitaxel 14Bevacizumab 14fludarabine 12Gemcitabine 11tislelizumab 10Ipilimumab 10spartalizumab 9Irinotecan 9atezolizumab 8Docetaxel 8Oxaliplatin 7Leucovorin 7Fluorouracil 7Capecitabine 6sintilimab 5Interleukin-2 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 4sotorasib 4pazopanib 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × methoxyamine × Other solid neoplasm × Clear all
NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡